Literature DB >> 16870714

Influence of increased CD4 cell counts on the genetic variability of hepatitis C virus in patients co-infected with human immunodeficiency virus I.

Xue-Ping Wang1, Leslie Goodwin, Pamela Kahn, Craig Gawel, Cheston B Cunha, Benjamin Laser, Benjamin Sahn, Mark H Kaplan.   

Abstract

In order to study the effect of increased CD4 cell counts on the biology of hepatitis C virus (HCV), we analyzed the genetic variability of HCV generated over 8 y in eight human immunodeficiency virus-1 (HIV-1) and HCV co-infected patients. This was a retrospective study in which HIV patients were selected who had profound immune impairment evident over four years and were co-infected with HCV genotype 1 and who then went on highly active antiretroviral therapy (HAART). These patients achieved different degrees of immune reconstitution, measured as increased CD4 cell counts during a 4- to 8-y period, following initiation of HAART. HCV genetic variability was determined by measuring the genetic diversity (Hamming distance, HD), and complexity (number of viral variants) in plasma samples collected at yearly intervals just before and after the initiation of HAART. The parameters were assessed by molecular cloning and sequencing of a 575-bp fragment including the HCV envelope 1 and envelope 2 genes (E1/E2), containing the hypervariable region 1 (HVR1). significantly increased HVR1 genetic diversity was observed in analyzed samples where the patients' CD4 cell counts were > or =100 compared with CD4 cell counts <100. A significant increase in genetic diversity in HVR1 was detected in co-infected patients whose CD4 cell counts increased from <100 to >400 over a period of more than 4 y of HAART therapy. This was in contrast to a minimal increase in HCV genetic diversity of HVR1 occurring in patients whose CD4 cell counts failed to rise much over 200 over 7 y of follow up. Insertion and deletion of HCV genomic fragments in the E1/E2 region was documented in one patient who developed fulminant hepatitis C.

Entities:  

Mesh:

Year:  2006        PMID: 16870714      PMCID: PMC2291784     

Source DB:  PubMed          Journal:  J Biomol Tech        ISSN: 1524-0215


  21 in total

1.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

2.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

3.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

4.  Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus.

Authors:  Anne Marie Roque-Afonso; Mathieu Robain; Danielle Simoneau; Patricia Rodriguez-Mathieu; Michèle Gigou; Laurence Meyer; Elisabeth Dussaix
Journal:  J Infect Dis       Date:  2002-02-28       Impact factor: 5.226

5.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection.

Authors:  I Bica; B McGovern; R Dhar; D Stone; K McGowan; R Scheib; D R Snydman
Journal:  Clin Infect Dis       Date:  2001-01-23       Impact factor: 9.079

6.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group.

Authors:  Kenneth E Sherman; Susan D Rouster; Raymond T Chung; Natasa Rajicic
Journal:  Clin Infect Dis       Date:  2002-02-06       Impact factor: 9.079

7.  Interpretation of undetectable hepatitis C virus RNA levels in HIV-hepatitis C virus co-infection.

Authors:  Curtis L Cooper; D William Cameron
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

8.  Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.

Authors:  Didier Neau; Anne-Christine Jouvencel; Elisabeth Legrand; Pascale Trimoulet; Tatiana Galperine; Isabelle Chitty; Michel Ventura; Brigitte Le Bail; Philippe Morlat; Jean-Yves Lacut; Jean-Marie Ragnaud; Michel Dupon; Hervé Fleury; Marie-Edith Lafon
Journal:  J Med Virol       Date:  2003-09       Impact factor: 2.327

9.  Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Authors:  Jennifer M Babik; Mark Holodniy
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 10.  Genetic diversity and evolution of hepatitis C virus--15 years on.

Authors:  Peter Simmonds
Journal:  J Gen Virol       Date:  2004-11       Impact factor: 3.891

View more
  3 in total

1.  The hepatitis C virus 5'UTR genomic region remains highly conserved under HAART: a 4- to 8-year longitudinal study from HCV/HIV co-infected patients.

Authors:  Franco Moretti; Federico Bolcic; Lilia Mammana; Maria Belen Bouzas; Natalia Laufer; Jorge Quarleri
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

Review 2.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

3.  Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection.

Authors:  Cassandra B Jabara; Fengyu Hu; Katie R Mollan; Sara E Williford; Prema Menezes; Yan Yang; Joseph J Eron; Michael W Fried; Michael G Hudgens; Corbin D Jones; Ronald Swanstrom; Stanley M Lemon
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.